To continue this statement, making and supplying medicines faster is the cornerstone of this programme. We must evolve and innovate towards new modes of action and harness the power of innovation as we navigate into a complex paradigm for biologics' development and manufacture.

 

With the rise of new treatments and the increased pace of molecules emerging through the pipeline, this is an opportunity to drive innovation and evolve to achieve better patient outcomes.

 

Every patient's time is limited; let's use it wisely.